The global diabetic nephropathy market is experiencing significant growth, with revenues reaching around US$ 2.1 billion in 2023 and projected to climb to US$ 3.6 billion by 2032. This growth, marked ...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...